Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVN NASDAQ:MREO NASDAQ:TRML NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$21.41-1.6%$20.00$13.30▼$30.03$1.29B0.85512,759 shs485,190 shsMREOMereo BioPharma Group$2.05+2.5%$1.82$1.47▼$4.72$318M0.451.31 million shs1.47 million shsTRMLTourmaline Bio$47.90$37.59$11.56▼$48.27$1.23B2.27595,808 shs460,095 shsTRVITrevi Therapeutics$10.36-2.5%$8.44$2.36▼$11.11$1.29B0.742.01 million shs1.56 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-1.56%+2.83%+12.57%-5.52%-23.86%MREOMereo BioPharma Group+2.50%+4.59%+18.50%+15.82%-54.55%TRMLTourmaline Bio0.00%+0.06%+0.42%+159.20%+72.30%TRVITrevi Therapeutics-2.54%+3.70%+29.82%+51.02%+223.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$21.41-1.6%$20.00$13.30▼$30.03$1.29B0.85512,759 shs485,190 shsMREOMereo BioPharma Group$2.05+2.5%$1.82$1.47▼$4.72$318M0.451.31 million shs1.47 million shsTRMLTourmaline Bio$47.90$37.59$11.56▼$48.27$1.23B2.27595,808 shs460,095 shsTRVITrevi Therapeutics$10.36-2.5%$8.44$2.36▼$11.11$1.29B0.742.01 million shs1.56 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-1.56%+2.83%+12.57%-5.52%-23.86%MREOMereo BioPharma Group+2.50%+4.59%+18.50%+15.82%-54.55%TRMLTourmaline Bio0.00%+0.06%+0.42%+159.20%+72.30%TRVITrevi Therapeutics-2.54%+3.70%+29.82%+51.02%+223.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 2.67Moderate Buy$41.2092.43% UpsideMREOMereo BioPharma Group 2.57Moderate Buy$7.40260.98% UpsideTRMLTourmaline Bio 2.00Hold$45.65-4.70% DownsideTRVITrevi Therapeutics 2.89Moderate Buy$21.75109.94% UpsideCurrent Analyst Ratings BreakdownLatest MREO, ELVN, TRML, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025MREOMereo BioPharma GroupZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MREOMereo BioPharma GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TRMLTourmaline BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MREOMereo BioPharma GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TRMLTourmaline BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TRVITrevi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/15/2025TRMLTourmaline BioBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$35.00 ➝ $48.009/11/2025TRMLTourmaline BioPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$65.00 ➝ $48.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AMREOMereo BioPharma Group$10M32.60N/AN/A$0.39 per share5.26TRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)Latest MREO, ELVN, TRML, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025ELVNEnliven Therapeutics-$0.43N/AN/AN/AN/AN/A11/11/2025Q3 2025MREOMereo BioPharma Group-$0.0035N/AN/AN/A$3.70 millionN/A11/6/2025Q3 2025TRMLTourmaline Bio-$0.96N/AN/AN/AN/AN/A11/5/2025Q3 2025TRVITrevi Therapeutics-$0.10N/AN/AN/AN/AN/A8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/13/2025Q2 2025TRMLTourmaline Bio-$0.94-$0.90+$0.04-$0.90N/AN/A8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A32.5832.58MREOMereo BioPharma GroupN/A8.138.13TRMLTourmaline BioN/A24.6824.68TRVITrevi TherapeuticsN/A22.4222.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%MREOMereo BioPharma Group62.83%TRMLTourmaline Bio91.89%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics25.90%MREOMereo BioPharma Group5.50%TRMLTourmaline Bio13.00%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableTRMLTourmaline Bio4425.69 million22.35 millionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableMREO, ELVN, TRML, and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Reaches New 52-Week High - Here's WhyOctober 14, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Time to Sell?October 13, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comBrokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.75October 9, 2025 | americanbankingnews.comTrevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual MeetingOctober 8, 2025 | prnewswire.comCantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)October 7, 2025 | theglobeandmail.comTrevi Therapeutics (TRVI) Receives a Buy from Leerink PartnersOctober 7, 2025 | theglobeandmail.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from AnalystsOctober 4, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month High - Here's What HappenedOctober 3, 2025 | marketbeat.comTrevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific DebutSeptember 23, 2025 | finance.yahoo.comHow Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025September 20, 2025 | finance.yahoo.comTrevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025September 18, 2025 | prnewswire.comHaduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan StanleySeptember 11, 2025 | msn.comTrevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comTrevi spikes as B. Riley reportedly cites deal prospectsAugust 28, 2025 | msn.comTrevi Therapeutics to Participate in Upcoming September ConferencesAugust 28, 2025 | prnewswire.comMorgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationAugust 22, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)August 13, 2025 | theglobeandmail.comTrevi Therapeutics: Optimism Amid Earnings Call InsightsAugust 13, 2025 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansAugust 10, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMREO, ELVN, TRML, and TRVI Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$21.41 -0.34 (-1.56%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$21.40 -0.01 (-0.05%) As of 10/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Mereo BioPharma Group NASDAQ:MREO$2.05 +0.05 (+2.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.04 -0.01 (-0.68%) As of 10/17/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Tourmaline Bio NASDAQ:TRML$47.90 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$47.92 +0.02 (+0.04%) As of 10/17/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Trevi Therapeutics NASDAQ:TRVI$10.36 -0.27 (-2.54%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.44 +0.09 (+0.82%) As of 10/17/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
